The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Privately-held Chinese developer of molecular glue degraders for cancer treatment Degron Therapeutics has entered into a collaboration and exclusive license agreement with Japan’s largest drugmaker Takeda Pharma. 23 May 2024
Basel, Switzerland-based SixPeaks Bio emerged from stealth mode yesterday, with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors. 23 May 2024
MilliporeSigma, the US and Canada Life Science business of Germany’s Merck KGaA, has signed a definitive agreement to acquire USA-based Mirus Bio, a specialist in the development and commercialization of transfection reagents. 23 May 2024
The US National Institutes of Health (NIH) has issued a first-of-its-kind draft policy proposal to promote equal access to products stemming from NIH-owned inventions. 23 May 2024
hares of French immunotherapy company OSE Immunotherapeutics were up almost 15% at 8.33 euros mid-morning on news of an expand partnership with German family-owned pharma major Boehringer Ingelheim. 23 May 2024
Roche’s Japan-based majority-owned company Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), in the Asian country. 23 May 2024
Japanese drugmaker Daiichi Sankyo has established two research institutes: DS Research Institute Boston and DS Research Institute Munich, in Cambridge, Massachusetts, USA and Munich, Germany, respectively. 23 May 2024
Cell engineering company MaxCyte has entered into a strategic platform license agreement with Legend Biotech, another company focused on cell therapies. 23 May 2024
Shares of UK immune-oncology company Roquefort Therapeutics rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. 23 May 2024
SpyBiotech, a biotechnology company specializing in innovative vaccine platforms, has entered into a research agreement with the University of Oxford. 23 May 2024
A new cost-cutting campaign from New York-based Pfizer demonstrates the intensity of the firm’s focus on ensuring operational efficiencies. 23 May 2024
Japanese drugmaker Otsuka Pharmaceutical and its US subsidiary have decided to terminate the development of the novel compound AVP-786, which was being studied as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease. 23 May 2024
Biomarker-driven clinical research and development company Precision for Medicine has announced that Harpreet Singh has joined the Maryland firm as chief medical officer. 22 May 2024
US biotech major Biogen today revealed it plans to acquire privately-held Human Immunology Biosciences (HI-Bio), in a bid to expand its rare disease portfolio. 22 May 2024
Privately-held Swiss company Swixx Biopharma today announced a strategic acquisition of Biopas, one of Latin America’s leading marketing and distribution companies for international biopharmaceutical firms. 22 May 2024